31 October 2023
31 October 2023
A Loqtorzi/chemotherapy combination has been approved as a first-line therapy in adults with metastatic or recurrent locally advanced NPC.
An EMA safety panel concluded that available evidence does not prove that GLP-1 receptor agonists cause thyroid cancer.
BGMA’s technical director, Paul Fleming, discusses changes to the UK pharmaceutical supply chain and how to maintain resilience.
If approved, the Opdivo/chemo combination would be the first of its kind to receive European authorisation for 1L urothelial cancer.
The NDA is based on data from the study assessing tovorafenib as a once-weekly monotherapy in relapsed or progressive paediatric low-grade glioma.
Genentech is one of many companies using Sosei Heptares GPCR know-how, with AbbVie, Eli Lilly and Pfizer all on the company’s books.
ALX-001 is currently being studied in a Phase Ib safety study and designs for a Phase II ALX-001 proof-of-concept study are underway.
Eric Schmidt and Ken Griffin have led the funding round, donating a government-matched $10m each.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.
Give your business an edge with our leading industry insights.
